

# Jadenu - (90, 360 mg; Tablet, Oral)

Generic Name	Deferasirox	Innovator	Novartis
Dosage	90, 360 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	Indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older		
Complexities	Yes		

### **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

# **Executive Summary**

Please Contact contact@researchdelta.com to get Detailed Information.

#### **Patent Status**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact contact@researchdelta.com to get Detailed Information.

### **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.



# Jadenu - (180 mg; Tablet, Oral)

Generic Name	Deferasirox	Innovator	Novartis
Dosage	180 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	Jadenu is indicated for the treatment of chronically elevated levels of iron in the blood caused by repeated blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.		
Complexities	Yes		

### **Chronology Of Events**

Please Contact contact@researchdelta.com to get Detailed Information.

### **Executive Summary**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

#### **Patent Status**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

## **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.